Zusammenfassung
Die Myotoxizität von Chloroquin und Hydroxychloroquin ist langjährig bekannt. Üblicherweise kann es dosisabhängig in den ersten 24 Monaten der Medikation zur Entwicklung einer Gliedergürtelschwäche im Rahmen einer vakuolären Myopathie kommen. Wir berichten über einen Fall mit Ausbildung einer Muskelschwäche nach siebenjähriger Einnahme von täglich 250 mg Chloroquinphosphat (=155 mg Chloroquinbase). Auch nach langjähriger, scheinbar gut vertragener Chloroquinmedikation muss auf die Ausbildung relevanter Nebenwirkungen geachtet werden.
Summary
The myotoxicity of chloroquine and hydroxychloroquine has been known for decades. Limb-girdle weakness due to a vacuolar myopathy may occur occasionally in a dose-dependent manner during the first 24 months on chloroquine. However, we report on a case in which muscular weakness developed after a daily intake of 250 chloroquine phosphate (= 155 mg chloroquine base) for a period of 7 years. Even after long-term and apparently well-tolerated chloroquine treatment, the occurrence of severe side-effects is possible.
This is a preview of subscription content, log in via an institution to check access.
References
Avina-Zubieta JA, Johnson ES, Suarez-Almazor ME, Russell AS (1995) Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature. Br J Rheumatol 34:166–170
Drenckhahn D, Lüllmann-Rauch R (1979) Experimental myopathy induced by amphiphilic cationic compounds including several psychotropic drugs. Neuroscience 4:549–562
Dubowitz V (1985) Muscle biopsy. A practical approach, 2. Aufl. Baillire Tindall, London
Erringer A, Colville P (1967) Chloroquine neuromyopathy associated with keratopathy and retinopathy. Br Med J 2:219–220
Estes ML, Ewing-Wilson D, Chou SM, Mitsumoto H, Hanson M, Shirey E, Ratliff NB (1987) Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 82:447–455
Furst DE (1996) Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 5 Suppl 1:S11–S15
Müller-Höcker J, Schmid H, Weiss M, Dendorfer U, Braun GS (2003) Chloroquine-induced phospholipidosis of the kidney mimicking Fabry’s disease: case report and review of the literature. Hum Pathol 34:285–289
Sieb JP, Gillessen T (2003) Iatrogenic and toxic myopathies. Muscle Nerve 27:142–156
Sieb JP (2004) Myopathies due to drugs, toxins, and nutritional deficiency. In: Engel AG, Franzini-Armstrong C (eds) Myology, 3rd edition, McGraw-Hill, New York (im Druck)
Whisnant JP, Espinosa RE, Kierland RR, Lambert EH (1963) Chloroquine neuromyopathy. Proc Mayo Clin 38:501
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Haberl, A., Fischer, P., Pongratz, D. et al. Chloroquin-induzierte Myopathie. Z. Rheumatol. 64, 274–276 (2005). https://doi.org/10.1007/s00393-005-0576-0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00393-005-0576-0